If approved, BBP-418 has the potential to become the first and only therapy for individuals living with LGMD2I/R9 and may represent the first approved treatment for any form of LGMD.

BridgeBio Pharma Inc. – BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9